Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
نویسندگان
چکیده
منابع مشابه
Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under...
متن کاملIpilimumab: a promising immunotherapy for melanoma.
Antibody-based targeting of the immune suppressor molecule cytotoxic T-lymphocyte antigen 4 (CTLA-4) with ipilimumab has been studied in metastatic melanoma in a number of clinical trials, including a recent phase III trial. This marks the first randomized clinical trial reporting an overall survival benefit using immune modulation in metastatic melanoma. Along with its therapeutic benefits, ip...
متن کاملImproved survival with ipilimumab in patients with metastatic melanoma.
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic ...
متن کاملSerum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of treatment. We analyzed serum from patients with metastatic melanoma (247 of 273, 90.4%) randomly assigned to receive ipilimumab or gp100 peptide vacc...
متن کاملVemurafenib and ipilimumab have improved overall survival in patients with metastatic melanoma. New Targeted Therapies in Melanoma
October 2013, Vol. 20, No. 4 Introduction The worldwide incidence of melanoma has increased over the past few decades, with more than 132,000 people diagnosed with the disease every year.1 In the United States, nearly 9,500 individuals will die of melanoma in 2013.2 Surgery has been the mainstay of treatment for localized disease. However, despite adequate surgery and approved adjuvant treatmen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Dermatology Research and Practice
سال: 2012
ISSN: 1687-6105,1687-6113
DOI: 10.1155/2012/182157